Cancer Therapy News and Research

RSS

Belfer Foundation funds new translational cancer institute

The Arthur and Rochelle Belfer Foundation has pledged $8 million to create the Arthur and Rochelle Belfer Institute of Hematology and Medical Oncology at Weill Medical College of Cornell University.

25 Jul 2006

Researchers isolate rare cancer stem cells that cause leukemia

Researchers at Dana-Farber Cancer Institute and Children's Hospital Boston and their colleagues have isolated rare cancer stem cells that cause leukemia in a mouse model of the human disease.

18 Jul 2006

Herceptin-linked nanoparticles for targeted cancer therapy

Albumin nanoparticles have recently proven their mettle as anticancer agents with the 2005 approval of Abraxane to treat metastatic breast cancer.

17 Jul 2006

Diblock copolymer micellar nanoparticles decorated with annexin-A5 proteins

One of the banes of modern cancer therapy is that clinicians and patients must often wait months before they can tell if a given treatment is working.

17 Jul 2006

Potential new diagnostic test and treatment for lung cancer

University of York spinout company, Cizzle Biotechnology, has secured venture capital funding from the White Rose Technology Seedcorn Fund to continue its development of a potential new diagnostic test and treatment for lung cancer.

17 Jul 2006

FoxM1 regulates the expression of oestrogen receptors in breast cancer

Research just published online in the "Journal of Biological Chemistry" identifies a new molecule involved in the regulation of oestrogen receptors (ER) expression in breast cancer.

12 Jul 2006

Determining the genetic composition of brain cancers informs treatment, predicts outcome

Research confirms that determining the genetic composition of brain cancers can better inform doctors and patients for treatment options and prognosis.

11 Jul 2006

Combination of anastrozole and a synthetic hormone called goserelin may slow male breast cancer growth

Medical oncologists across the nation want to know whether a certain drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it's in an advanced stage.

10 Jul 2006

New imaging system could track cancer growth

A new imaging system currently entering clinical testing could allow doctors to track the process of cancer growth in real-time, scientists have said.

27 Jun 2006

For men with prostate cancer, treatment information fails to address fears

Men with prostate cancer make emotionally driven treatment decisions influenced by anecdote and misconception rather than consideration of clinical trial evidence, according to a new study.

27 Jun 2006

New highly successful method of freezing human eggs

A new and highly successful method of freezing human eggs will help to even out the current inequality between men and women.

19 Jun 2006

Liquorice compounds could be a key component for cheaper, more effective liver cancer treatment

Liquorice compounds could be a key component for cheaper, more effective liver cancer treatment, reports Chemistry & Industry magazine.

8 Jun 2006

Reovirus could be used to treat many forms of advanced cancer

An experimental drug called Reolysin may give hope to patients suffering from advanced cancers, according to research presented at this year's meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2006

Glivec the best news yet for cancer victims

In what is great news for those suffering from chronic myeloid leukaemia (CML), the drug Glivec looks like being one of the biggest breakthroughs in cancer therapy for a years.

7 Jun 2006

Exposing cancer more quickly

Previous methods for uncovering cancer are old and inaccurate. Now, data analysts at Norut IT Research in Norway are moving cancer treatment forward.

7 Jun 2006

Trastuzumab results promising for HER-2 positive breast cancer patients

Researchers have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug.

7 Jun 2006

Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia

The overall survival of most people with chronic myelogenous leukemia (CML) treated with imatinib (Gleevec, STI-571) is extremely high and the relapse rate is quite low, according to new data from a study out of the Oregon Health & Science University Cancer Institute.

6 Jun 2006